Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.45 |
| ▸ | DYRK2 | Q92630 | 5/20 | 0.45 |
| ▸ | DYRK3 | O43781 | 4/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.45 |
| ▸ | CDK2 | P24941 | 4/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.45 |
| ▸ | CDK9 | P50750 | 2/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 13/20 | 0.44 |
| ▸ | TGFBR2 | P37173 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16620325 | 0.82 | TNF (0.49) | TNFDYRK1ADYRK2DYRK3CCNA2 | |
| SCHEMBL15674118 | 0.79 | TNF (0.46) | TNFDYRK1ADYRK2DYRK3CCNA2 | |
| SCHEMBL16620555 | 0.79 | DYRK1A (0.47) | TNFDYRK1ADYRK2DYRK3CCNA2 | |
| SCHEMBL15638125 | 0.79 | TGFBR1 (0.45) | TGFBR1TGFBR2 | |
| SCHEMBL7889752 | 0.79 | TGFBR1 (0.51) | TGFBR1TGFBR2KDM4E | |
| SCHEMBL31691002 | 0.79 | TGFBR1 (0.45) | TGFBR1TGFBR2 | |
| SCHEMBL16620406 | 0.77 | TNF (0.44) | TNFDYRK1ADYRK2DYRK3CCNA2 | |
| SCHEMBL16620525 | 0.75 | RET (0.43) | TNFDYRK1ADYRK2DYRK3CCNA2 | |
| SCHEMBL3452842 | 0.75 | TNF (0.56) | TNFDYRK1ADYRK2DYRK3CCNA2 | |
| SCHEMBL13080170 | 0.75 | TGFBR1 (0.46) | TGFBR1TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117417340-A | Preparation method of 6-chloroimidazo [1,2-b ] pyridazine-3-carbonitrile | 山东省科学院菏泽分院 | 2024-01-19 | — | — | CN | claimed |
| CN-112321592-B | Synthesis method of 6-chloroimidazo [1,2-b ] pyridazine-3-carbonitrile | 山东省科学院菏泽分院 | 2022-03-04 | — | — | CN | claimed |
| CN-112321592-A | Synthesis method of 6-chloroimidazo [1,2-b ] pyridazine-3-carbonitrile | 山东省科学院菏泽分院 | 2021-02-05 | — | — | CN | claimed |
| CN-117417340-B | Preparation method of 6-chloroimidazo [1,2-b ] pyridazine-3-carbonitrile | 山东省科学院菏泽分院 | 2025-08-26 | — | — | CN | disclosed |
| CN-117417340-B | Preparation method of 6-chloroimidazo [1,2-b ] pyridazine-3-carbonitrile | 山东省科学院菏泽分院 | 2025-08-26 | — | — | CN | disclosed |
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| CN-114989173-B | Imidazole compound, pharmaceutical composition and application thereof | 广州市恒诺康医药科技有限公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20240043427-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-02-08 | — | — | US | disclosed |
| CN-117417340-A | Preparation method of 6-chloroimidazo [1,2-b ] pyridazine-3-carbonitrile | 山东省科学院菏泽分院 | 2024-01-19 | — | — | CN | disclosed |
| CN-117417340-A | Preparation method of 6-chloroimidazo [1,2-b ] pyridazine-3-carbonitrile | 山东省科学院菏泽分院 | 2024-01-19 | — | — | CN | disclosed |
| CN-117417340-A | Preparation method of 6-chloroimidazo [1,2-b ] pyridazine-3-carbonitrile | 山东省科学院菏泽分院 | 2024-01-19 | — | — | CN | disclosed |
| EP-2614062-A1 | IMIDAZO [1, 2]PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2013-07-17 | — | — | EP | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| WO-2012034091-A1 | IMIDAZO [1, 2] PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012034091-A1 | IMIDAZO [1, 2] PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
| EP-2217601-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009060197-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043427-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | TNF 2852/4885DYRK1A 2886/4885DYRK2 2847/4885 |
| US-12110294-B2 | CD73 compounds | ENTPD5, ENTPD1, NT5E | TNF 2894/4885DYRK1A 3442/4885DYRK2 3401/4885 |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | TNK2, CNKSR1, BMP2K | TNF 2369/4885DYRK1A 1516/4885DYRK2 1560/4885 |
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | TNF 4372/4885DYRK1A 588/4885DYRK2 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.